Phaseline

Targets › NR3C1

NR3C1 (Glucocorticoid receptor): drug programs, companies and trials

53 programs from 47 companies in 222 trials: 77 Phase 4, 67 Phase 2, 44 Phase 3, 34 Phase 1; Immunology, Other, Oncology; next expected readout Nov 2026.

Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. (UniProt, P04150)

Open in Phaseline: the race on NR3C1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wake Forest University Health SciencesTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Central Centrifugal Cicatricial Alopecia (CCCA)Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
The University of Hong KongTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Patella FractureDec 2026
Diakonhjemmet HospitalTriamcinolone acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Osteoarthritis Thumb; Carpal Tunnel SyndromeFeb 2027
Christian CandrianDexamethasone Sodium Phosphate
Glucocorticoid receptor agonist
NR3C1Phase 4Total Knee ReplacementApr 2027
AstraZenecaBudesonide (PT027)
Glucocorticoid receptor agonist
NR3C1Phase 4Chronic Obstructive Pulmonary Disease; Asthma; Functional Dyspepsia; IgA Nephropathy …May 2027
Hospital JP GarrahanESHAP
Combination chemotherapy: Etoposide (topoisomerase II inhibitor), Methylprednisolone (cort
TOP2B, NR3C1Phase 4Pediatric Hodgkin's DiseaseOct 2027
McMaster UniversityBeclomethasone Dipropionate
Glucocorticoid receptor agonist
NR3C1Phase 4AsthmaJun 2028
Santhera Pharmaceuticalsvamorolone
Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist
NR3C1, NR3C2Phase 4Duchenne Muscular DystrophySep 2028
Alimera SciencesFluocinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Diabetic Macular Edema; Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Diabetic Macular Edema (DME); Radiation RetinopathyOct 2028
Igor Wilderman. MDTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Back Pain Lower BackDec 2029
ViatrisFluticasone Propionate
Glucocorticoid receptor agonist
NR3C1Phase 4Allergic Rhinitis Due to Allergens–
Centre hospitalier de l'Université de Montréal (CHUM)Triamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Primary Gonarthrosis–
Pacira PharmaceuticalsTriamcinolone
Glucocorticoid receptor agonist
NR3C1Phase 3Glenohumeral Osteoarthritis; Pain; Osteoarthritis, Knee; Osteoarthritis of Knee …Dec 2026
Corcept Therapeuticsrelacorilant
Glucocorticoid receptor antagonist
NR3C1Phase 3Ovarian Neoplasm; Cushing Syndrome; Ovarian Cancer; Adenocarcinoma …Dec 2026
TiohundraHydrocortisone
Glucocorticoid receptor agonist
NR3C1Phase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Pituitary Adenoma; Adrenal Insufficiency; Shock …Jan 2027
Leiden University Medical CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 3Female ContraceptionJun 2027
YiLinMethylprednisolone sodium succinate
Glucocorticoid receptor agonist
NR3C1Phase 3Large Infarct CoreSep 2027
Tang-Du Hospitalmethylprednisolone sodium succinate
Glucocorticoid receptor agonist
NR3C1Phase 3Acute Ischemic Stroke; Ischemia StrokeDec 2027
Optinose USFluticasone Propionate (OPN-375)
Glucocorticoid receptor agonist
NR3C1Phase 3Chronic Rhinosinusitis Without Nasal Polyps; Allergic Rhinitis; Healthy; Chronic Cough …Mar 2028
Sint MaartenskliniekMethylprednisolone Acetate
Glucocorticoid receptor agonist
NR3C1Phase 3Hand OsteoarthritisApr 2028
Jeremy Keenan, MD, MPHDexamethasone sodium phosphate
Glucocorticoid receptor agonist
NR3C1Phase 3Acanthamoeba KeratitisJul 2029
Wan-Jin ChenMethylprednisolone sodium succinate
Glucocorticoid receptor agonist
NR3C1Phase 3Acute Ischemic StrokeJun 2030
Teva Branded Pharmaceutical Products R&DFluticasone Propionate
Glucocorticoid receptor agonist
NR3C1Phase 3Asthma–
Laboratorios Sophia S.A de C.V.Moxifloxacin (PRO-232)
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
GYRB, NR3C1Phase 3Cataract Extraction–
VA Office of Research and DevelopmentTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 3Osteoarthritis of the Knee–
Christiaan VinkersMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Treatment-resistant PTSDNov 2026
Daniel Raper, MBBSMethylprednisolone sodium succinate
Glucocorticoid receptor agonist
NR3C1Phase 2Headaches Associated With Subarachnoid Hemorrhage (SAH)Jan 2027
Chelsea and Westminster NHS Foundation TrustMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Labor, InducedMar 2027
Memorial Sloan Kettering Cancer CenterTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 2GlioblastomaJul 2027
University of PalermoClobetasol Propionate
Glucocorticoid receptor agonist
NR3C1Phase 2Oral Lichen PlanusOct 2027
Memorial Sloan Kettering Cancer CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Metastatic Breast CancerOct 2027
Corcept TherapeuticsDazucorilant (CORT113176)
Glucocorticoid receptor antagonist
NR3C1Phase 2Amyotrophic Lateral SclerosisNov 2027
Université du Québec à Trois-RivièresTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 2Trapeziometacarpal OsteoarthritisDec 2027
Memorial Sloan Kettering Cancer CenterMometasone Furoate
Glucocorticoid receptor agonist
NR3C1Phase 2Breast CancerOct 2028
University of Alabama at BirminghamBeclomethasone Dipropionate
Glucocorticoid receptor agonist
NR3C1Phase 2AsthmaDec 2028
Oticara AustraliaBetamethasone
Glucocorticoid receptor agonist
NR3C1Phase 2Chronic Rhinosinusitis (Diagnosis); Hemiplegia; Myofascial Pain Dysfunction Syndrome; Anaphylactic Reaction …–
Malmö UniversityClobetasol Propionate
Glucocorticoid receptor agonist
NR3C1Phase 2Oral Lichen Planus–
Post Graduate Institute of Medical Education and Research, ChandigarhDeflazacort
Glucocorticoid receptor agonist
NR3C1Phase 2Allergic Bronchopulmonary Aspergillosis–
University of ChicagoMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Breast Cancer–
Corcept TherapeuticsMiricorilant
Glucocorticoid receptor modulator
NR3C1Phase 2Nonalcoholic Steatohepatitis (NASH)–
Universitas PadjadjaranTriamcinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 2Keloid Scars–
The Methodist Hospital Research InstituteDexamethasone Sodium Phosphate
Glucocorticoid receptor agonist
NR3C1Phase 1Ureteral Stent-Related SymptomDec 2026
Eupraxia PharmaceuticalsEP-104GI
Extended-release fluticasone propionate for gastrointestinal administration
NR3C1Phase 1Eosinophilic EsophagitisDec 2026
Corcept TherapeuticsNenocorilant
Glucocorticoid receptor antagonist
NR3C1Phase 1NeoplasmsJan 2027
M.D. Anderson Cancer CenterCB-NK-TGF-betaR2-/NR3C1-
Cord blood-derived engineered natural killer cells with deleted TGF-betaR2 and NR3C1 (gluc
TGFBR2, NR3C1Phase 1Recurrent GliosarcomaJan 2027
Venkatesh SampathCiclesonide
Glucocorticoid receptor agonist
NR3C1Phase 1Bronchopulmonary DysplasiaMay 2027
Montefiore Medical CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 1Cervical PreparationJun 2027
M.D. Anderson Cancer CenterCytokine-treated Veto Cells
CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel
IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2Phase 1Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal CancerDec 2027
Pop Test OncologyOrg-34517 (PT150)
Glucocorticoid receptor antagonist
NR3C1Phase 1Alcohol Use DisorderJul 2028
University of California, DavisDesonide
Glucocorticoid receptor agonist
NR3C1Phase 1Healthy–
University Hospital, LilleTRIXEO AEROSPHERE (BGF 160)
Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic
ADRB2, CHRM3, NR3C1Phase 1Copd–

Conditions

Asthma (8) Oral Lichen Planus (4) Breast Cancer (4) Chronic Obstructive Pulmonary Disease (3) Nicotine Dependence (3) Frozen Shoulder (2) IgA Nephropathy (2) Prostate Cancer (2) Hand Osteoarthritis (2) Cataract (2) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2)

Modalities

small molecule (48), mixed (4), other (1)

Companies

Corcept Therapeutics (4) Memorial Sloan Kettering Cancer Center (3) M.D. Anderson Cancer Center (2) Diakonhjemmet Hospital (1) University of Palermo (1) McMaster University (1) Christiaan Vinkers (1) Oticara Australia (1) Montefiore Medical Center (1) Universitas Padjadjaran (1) University of Alabama at Birmingham (1) AstraZeneca (1) University of Chicago (1) Daniel Raper, MBBS (1) Leiden University Medical Center (1) Venkatesh Sampath (1) Sint Maartenskliniek (1) Eupraxia Pharmaceuticals (1) Chelsea and Westminster NHS Foundation Trust (1) Wake Forest University Health Sciences (1)

Related targets

PGR (6) ADRB2 (3) IL12B (2) IL23A (2) HTR2A (2) CHRM3 (2) TGFBR2 (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.